Ivacaftor in French Patients With Cystic Fibrosis and a G551D Mutation
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the treatment with Ivacaftor remains
effective and safe in the patients with cystic fibrosis (and at least one G551D CFTR
mutation) in the real life setting, after the drug has been approved by the Health
authorities.